| Current Price | $20.39 | Mkt Cap | $3.3B |
|---|---|---|---|
| Open | $20.78 | P/E Ratio | 0.00 |
| Prev. Close | $20.39 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $20.31 - $20.86 | Volume | 1,716,630 |
| 52-Wk Range | $20.31 - $58.72 | Avg. Daily Vol. | 3,018,002 |
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
| Current Price | $20.39 | Mkt Cap | $3.3B |
|---|---|---|---|
| Open | $20.78 | P/E Ratio | 0.00 |
| Prev. Close | $20.39 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $20.31 - $20.86 | Volume | 1,716,630 |
| 52-Wk Range | $20.31 - $58.72 | Avg. Daily Vol. | 3,018,002 |
The best Bull and Bear pitches based on recency and number of recommendations.
Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More
This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More
Read the most recent pitches from players about ACAD.
Recs
pitbullsneedlove
(63.90)
Submitted: 8/15/2020 6:51:41 PM :
Start Price:
$39.85
NASDAQ:ACAD Score:
-70.59
It’s already profitable and I see a lot of uses for its medicine.
Recs
LifeScientist
(83.52)
Submitted: 7/2/2020 3:08:37 PM :
Start Price:
$52.08
NASDAQ:ACAD Score:
-92.03
The principal pipieline drug Nuplazid seeking fda approval is already market for Parkinson’s patients. Wow, my own Mom could benefit! ....we’ve been seeking a drug that would help her hallucinations w dementia. sNDA on dementia now....hope it works and is covered by insurance!
Recs
NHWeston102
(77.64)
Submitted: 5/2/2020 2:10:25 PM :
Start Price:
$47.37
NASDAQ:ACAD Score:
-101.18
Leading dementia treatment candidates.
Find the members with the highest scoring picks in ACAD.
TrackLadenburg (< 20) Score: +2,706.67
The Score Leader is the player with the highest score across all their picks in ACAD.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| jamrod02 | 49.43 | 12/20/2010 |
|
5Y | $0.77 | +2,548.40% | +230.14% | +2,318.25 | 0 Comment | |
| noobtery | 21.43 | 10/28/2010 |
|
5Y | $0.83 | +2,356.63% | +246.19% | +2,110.43 | 0 Comment | |
| Hornet41 | 53.04 | 12/22/2010 |
|
5Y | $0.90 | +2,165.30% | +227.93% | +1,937.37 | 0 Comment | |
| Ruckwerts | 26.19 | 12/1/2011 |
|
3Y | $0.93 | +2,092.47% | +229.80% | +1,862.67 | 0 Comment | |
| dsherid2 | 58.91 | 11/30/2011 |
|
1Y | $1.03 | +1,879.80% | +231.21% | +1,648.60 | 0 Comment | |
| Smog79 | < 20 | 8/12/2010 |
|
3W | $1.04 | +1,860.58% | +278.87% | +1,581.71 | 0 Comment | |
| drmanand | 41.67 | 7/14/2010 |
|
1Y | $1.11 | +1,737.27% | +276.44% | +1,460.82 | 1 Comment | |
| smallandmidcap | 88.06 | 8/10/2010 |
|
5Y | $1.13 | +1,704.42% | +267.30% | +1,437.12 | 0 Comment | |
| dmkj50 | < 20 | 10/27/2011 |
|
5Y | $1.17 | +1,642.59% | +221.65% | +1,420.93 | 0 Comment | |
| tappo3833 | 85.88 | 1/3/2011 |
|
1Y | $1.19 | +1,613.45% | +224.75% | +1,388.70 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
